236 related articles for article (PubMed ID: 36864243)
1. Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
Hood FE; Sahraoui YM; Jenkins RE; Prior IA
Oncogene; 2023 Apr; 42(15):1224-1232. PubMed ID: 36864243
[TBL] [Abstract][Full Text] [Related]
2. Differential functions of the KRAS splice variants.
Kochen Rossi J; Nuevo-Tapioles C; Philips MR
Biochem Soc Trans; 2023 Jun; 51(3):1191-1199. PubMed ID: 37222266
[TBL] [Abstract][Full Text] [Related]
3. A model for RAS mutation patterns in cancers: finding the sweet spot.
Li S; Balmain A; Counter CM
Nat Rev Cancer; 2018 Dec; 18(12):767-777. PubMed ID: 30420765
[TBL] [Abstract][Full Text] [Related]
4. Origin and Evolution of RAS Membrane Targeting.
García-España A; Philips MR
Oncogene; 2023 May; 42(21):1741-1750. PubMed ID: 37031342
[TBL] [Abstract][Full Text] [Related]
5. Quantification of spatiotemporal patterns of Ras isoform expression during development.
Newlaczyl AU; Coulson JM; Prior IA
Sci Rep; 2017 Jan; 7():41297. PubMed ID: 28117393
[TBL] [Abstract][Full Text] [Related]
6. The role of wild type RAS isoforms in cancer.
Zhou B; Der CJ; Cox AD
Semin Cell Dev Biol; 2016 Oct; 58():60-9. PubMed ID: 27422332
[TBL] [Abstract][Full Text] [Related]
7. Explaining the preponderance of Kras mutations in human cancer: An isoform-specific function in stem cell expansion.
Quinlan MP; Settleman J
Cell Cycle; 2008 May; 7(10):1332-5. PubMed ID: 18418066
[TBL] [Abstract][Full Text] [Related]
8. Strategies for Targeting KRAS: A Challenging Drug Target.
Wadood A; Ajmal A; Rehman AU
Curr Pharm Des; 2022; 28(23):1897-1901. PubMed ID: 35524675
[TBL] [Abstract][Full Text] [Related]
9. The Abundance of KRAS and RAS Gene Mutations in Cancer.
Stites EC
Methods Mol Biol; 2024; 2797():13-22. PubMed ID: 38570449
[TBL] [Abstract][Full Text] [Related]
10. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
11. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
12. Decoding RAS isoform and codon-specific signalling.
Newlaczyl AU; Hood FE; Coulson JM; Prior IA
Biochem Soc Trans; 2014 Aug; 42(4):742-6. PubMed ID: 25109951
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
14. Validation of Isoform- and Mutation-Specific RAS Antibodies.
Waters AM; Der CJ
Methods Mol Biol; 2021; 2262():91-103. PubMed ID: 33977472
[TBL] [Abstract][Full Text] [Related]
15. Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.
Johnson CW; Lin YJ; Reid D; Parker J; Pavlopoulos S; Dischinger P; Graveel C; Aguirre AJ; Steensma M; Haigis KM; Mattos C
Cell Rep; 2019 Aug; 28(6):1538-1550.e7. PubMed ID: 31390567
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of isoform-specific residue influence on GTP-bound HRas, KRas, and NRas.
Volmar AY; Guterres H; Zhou H; Reid D; Pavlopoulos S; Makowski L; Mattos C
Biophys J; 2022 Oct; 121(19):3616-3629. PubMed ID: 35794829
[TBL] [Abstract][Full Text] [Related]
17. Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling.
Adams LM; DeHart CJ; Drown BS; Anderson LC; Bocik W; Boja ES; Hiltke TM; Hendrickson CL; Rodriguez H; Caldwell M; Vafabakhsh R; Kelleher NL
J Biol Chem; 2023 Jan; 299(1):102768. PubMed ID: 36470426
[TBL] [Abstract][Full Text] [Related]
18. Absolute Quantification of Endogenous Ras Isoform Abundance.
Mageean CJ; Griffiths JR; Smith DL; Clague MJ; Prior IA
PLoS One; 2015; 10(11):e0142674. PubMed ID: 26560143
[TBL] [Abstract][Full Text] [Related]
19. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
Nussinov R; Tsai CJ; Jang H
Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
